The Cooper Companies stock (US2166481027): fiscal Q2 2026 results and outlook in focus for US investors

The Cooper Companies has reported fiscal Q2 2026 results and updated its full-year outlook, keeping attention on its contact-lens and women’s-health businesses as US investors weigh growth, margins and capital allocation.

The Cooper Companies reported its fiscal second quarter 2026 results and updated its outlook for the rest of the fiscal year, putting the focus on how its contact-lens and women’s-health activities are performing for investors in its US home market. According to a company filing published on 05/21/2026 and covering the quarter ended 04/30/2026, management detailed revenue trends in its CooperVision and CooperSurgical segments alongside profitability and cash-flow metrics, while also addressing capital allocation priorities for the remainder of fiscal 2026, as reported on 05/21/2026 according to investor relations disclosures.

For context, The Cooper Companies remains listed on Nasdaq under the ticker COO and continues to trade in US dollars, with the stock price and market capitalization data updated by the exchange and financial data providers as of 05/22/2026. The stock traded at 64.58 USD on Nasdaq on 05/22/2026, per data compiled as of 05/22/2026, providing a reference point for equity investors following the fiscal Q2 2026 update.

As of: 26.05.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: The Cooper Companies
• Sector/industry: Medical devices and supplies
• Headquarters/country: San Ramon, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: CooperVision contact lenses, CooperSurgical fertility and women’s-health products
• Home exchange/listing venue: Nasdaq (COO)
• Trading currency: USD

The Cooper Companies: core business model

The Cooper Companies operates as a global medical-device group focused on eye care and women’s health, with its current structure centered on the CooperVision and CooperSurgical business segments as outlined in its latest annual report for fiscal 2025, which was filed on 01/30/2026 and covers the year ended 10/31/2025. CooperVision primarily designs, manufactures and markets soft contact lenses, which are distributed to eye-care professionals and retailers in key regions including North America, Europe and Asia-Pacific, according to the same fiscal 2025 filing dated 01/30/2026.

CooperSurgical, by contrast, focuses on fertility solutions, contraceptive devices and other women’s-health products, catering to both healthcare providers and fertility clinics, as indicated in the fiscal 2025 Form 10-K published on 01/30/2026 for the year to 10/31/2025. The company positions itself as a specialist rather than a diversified conglomerate, with both segments targeting recurring demand driven by demographic trends such as aging populations, rising myopia prevalence and increased use of assisted reproductive technologies, based on management’s strategic commentary in the fiscal 2025 reporting dated 01/30/2026.

In terms of geographic footprint, The Cooper Companies emphasizes developed markets such as the United States and Western Europe while also expanding in emerging markets, particularly in Asia-Pacific, according to its fiscal 2025 annual report dated 01/30/2026. The business model relies on a combination of new product introductions, portfolio upgrades and distribution expansion, supported by research and development spending that management highlighted in its fiscal 2025 filings on 01/30/2026 as a key enabler of long-term growth.

From an operational perspective, The Cooper Companies maintains manufacturing facilities and distribution centers across several regions, which allows it to serve local markets while managing inventory and logistics, as described in the fiscal 2025 Form 10-K dated 01/30/2026. The company’s revenue streams are largely derived from recurring purchases of contact lenses and medical devices, which can support relatively stable cash flows when customer relationships and product performance remain strong, according to the same 01/30/2026 regulatory filing.

The corporate structure has remained focused on medical devices over the past two years, with no completed transformational spin-offs or divestitures reported that would alter the two main segments, based on a review of company disclosures and regulatory filings issued between 01/01/2024 and 05/21/2026. Management has, however, continued to refine the portfolio within each division through product launches and smaller targeted transactions, as referenced in investor communications around fiscal 2025 and fiscal Q2 2026 published up to 05/21/2026.

Main revenue and product drivers for The Cooper Companies

According to The Cooper Companies’ Form 10-K for fiscal 2025, filed on 01/30/2026 for the period ended 10/31/2025, CooperVision accounted for the majority of consolidated revenue, driven by sales of spherical, toric and multifocal soft contact lenses. Within this segment, daily disposable and silicone hydrogel lenses represented significant growth areas, reflecting patient and practitioner preferences for comfort and convenience, as reported in the 01/30/2026 filing for fiscal 2025.

CooperVision’s revenue is influenced by both volume growth and product mix, with higher value lenses typically supporting stronger average selling prices, according to management’s commentary in the fiscal 2025 annual report dated 01/30/2026. Regional dynamics also matter, as the company reported meaningful contributions from the Americas, EMEA and Asia-Pacific regions in its fiscal 2025 segment disclosures filed on 01/30/2026, highlighting the importance of broad geographic diversification.

CooperSurgical represents the second major revenue pillar, with contributions from fertility-related products, including consumables and equipment used in assisted reproductive technology procedures, as well as contraceptive and obstetric devices, based on the fiscal 2025 Form 10-K published on 01/30/2026. Demand in this segment is influenced by procedure volumes, innovation in fertility treatments and regulatory frameworks in key markets such as the United States and Europe, according to the same 01/30/2026 disclosure.

The fiscal Q2 2026 filing dated 05/21/2026, covering the quarter ended 04/30/2026, indicated that both segments continued to contribute to overall revenue, with detailed figures for the period’s sales, operating income and margin drivers. Management also discussed investments in new product platforms, including contact-lens technologies and fertility solutions, as part of its strategy to sustain growth and defend market share, according to the 05/21/2026 report covering fiscal Q2 2026.

Beyond pure revenue, The Cooper Companies’ performance is shaped by gross margin and operating margin trends, which depend on manufacturing efficiency, input costs and product mix. In its fiscal 2025 report filed on 01/30/2026, the company highlighted cost initiatives and supply-chain optimization efforts aimed at supporting margins in both CooperVision and CooperSurgical, and referenced ongoing initiatives again in the fiscal Q2 2026 disclosure dated 05/21/2026 for the quarter to 04/30/2026.

Research and development spending is another important driver, with The Cooper Companies allocating resources to new lens materials, digital tools for practitioners and enhanced women’s-health solutions, as outlined in the fiscal 2025 Form 10-K dated 01/30/2026. These investments can take several years to translate into commercial products and revenue but are presented by management as critical to sustaining competitiveness, according to commentary in the same 01/30/2026 document and subsequent fiscal Q2 2026 materials dated 05/21/2026.

Recent corporate actions and fiscal Q2 2026 update

In the fiscal Q2 2026 report released on 05/21/2026 for the quarter ended 04/30/2026, The Cooper Companies provided an update on revenue, earnings and cash flow, along with its full-year fiscal 2026 outlook, according to an investor relations publication dated 05/21/2026. The filing outlined key performance indicators for CooperVision and CooperSurgical, including comparisons with the prior-year quarter ended 04/30/2025, as required in the company’s regulatory disclosure on 05/21/2026.

Alongside the numerical results, management commented on demand patterns in the contact-lens market and in fertility and women’s-health procedures, noting factors such as clinic activity levels and patient volumes in major regions, based on the fiscal Q2 2026 materials published on 05/21/2026. The update also covered capital allocation, including ongoing investment in production capacity and research projects, and addressed the company’s approach to debt reduction and liquidity as of 04/30/2026, according to the same 05/21/2026 fiscal Q2 2026 report.

The company’s fiscal Q2 2026 communication on 05/21/2026 did not announce a transformational merger, spin-off or major divestiture that would structurally change the two-segment model of CooperVision and CooperSurgical. Instead, it focused on operational execution and the evolution of its guidance for the remainder of fiscal 2026, as summarized in management’s commentary dated 05/21/2026 for the quarter to 04/30/2026.

For US investors, the fiscal Q2 2026 numbers and guidance are relevant for assessing how The Cooper Companies is balancing growth investments with profitability in a competitive medical-device landscape. The interaction between contact-lens demand, procedure volumes in fertility and women’s health, and macroeconomic conditions such as consumer spending and healthcare utilization shapes expectations for future quarters, as inferred from the company’s outlook statements in the 05/21/2026 fiscal Q2 2026 release.

In addition to the regular quarterly update, The Cooper Companies’ governance and management structure remained stable through the period up to 05/21/2026, with no new chief executive or chief financial officer appointments announced in regulatory or investor communications over the preceding 90 days. This continuity provides context for investors interpreting the fiscal Q2 2026 results and updated outlook, as noted in the company’s filings and news releases through 05/21/2026.

Industry trends and competitive position

The Cooper Companies operates in the broader medical-device and healthcare-supplies industry, where contact-lens and women’s-health markets are influenced by demographic trends, clinical practice patterns and regulatory frameworks. Industry research providers and sector reports published ahead of and during 2025 and early 2026 have highlighted the continued global rise in myopia rates and the associated demand for vision-correction solutions, which supports structural growth in the contact-lens category, as discussed in sector analyses released up to 04/30/2026.

Within the soft contact-lens space, The Cooper Companies, through CooperVision, competes with other multinational manufacturers that also invest heavily in R&D and marketing, according to industry commentary and company filings dated between 01/01/2025 and 05/21/2026. Differentiation often comes from lens materials, comfort, oxygen permeability, replacement schedules and digital tools that help practitioners fit and manage patients, as inferred from product descriptions and marketing materials reviewed in that time frame.

In fertility and women’s health, CooperSurgical participates in markets that are shaped by clinic capacity, insurance coverage and evolving clinical approaches, based on healthcare sector publications and company disclosures through 05/21/2026. The segment faces both opportunities from increased awareness of fertility options and challenges from reimbursement and regulatory changes, which can vary significantly across countries and regions, according to policy-focused analyses available as of 04/30/2026.

The Cooper Companies has highlighted in its fiscal 2025 and fiscal Q2 2026 filings, dated 01/30/2026 and 05/21/2026 respectively, that it continues to prioritize investments in technology and manufacturing to maintain and extend its competitive position. This includes capacity expansions, quality management and incremental innovation across its product lines, as described in the same documents covering the fiscal 2025 and fiscal Q2 2026 periods.

For US equity investors, positioning within these industry trends is central to how The Cooper Companies might perform relative to broader indices and healthcare peers. Factors such as product launches, regulatory approvals, competitive pricing and macroeconomic conditions will likely influence both top-line growth and margin development, as illustrated by management’s sensitivity discussions in its fiscal 2025 and fiscal Q2 2026 investor communications dated 01/30/2026 and 05/21/2026, respectively.

Why The Cooper Companies matters for investors in its home market

As a Nasdaq-listed medical-device group with a focus on eye care and women’s health, The Cooper Companies represents an exposure to structural healthcare themes within the US equity market. For US-based investors who follow domestic listings, the company offers access to global contact-lens and fertility markets through a single stock denominated in US dollars, as indicated by exchange data for Nasdaq and company disclosures as of 05/22/2026.

From a portfolio-construction perspective, The Cooper Companies sits within the healthcare sector and can be compared with other medical-device and healthcare-supplies companies in terms of growth, profitability and capital allocation metrics. Sector classification providers and index compilers have continued to place the company in healthcare-related categories during 2025 and 2026, as reflected in sector overviews dated up to 04/30/2026.

Investors in the US home market may also focus on how The Cooper Companies navigates regulatory and reimbursement environments in its key markets, since changes in healthcare policy can affect demand for both contact lenses and women’s-health products. Company filings and sector commentary through 05/21/2026 indicate that management closely monitors these factors and incorporates them into its planning, including the guidance communicated in the fiscal Q2 2026 update dated 05/21/2026.

Liquidity and index inclusion are additional considerations for US investors following The Cooper Companies. The stock’s Nasdaq listing and its presence in certain healthcare or mid-cap indices, as reported by index providers and trading-venue data up to 05/22/2026, influence how some institutional and retail investors may gain exposure to the name, given that index-linked strategies and ETFs often track sector constituents.

What banks and research houses say about The Cooper Companies

No verified analyst coverage was identified at the time of publication.

Conclusion

The Cooper Companies’ fiscal Q2 2026 results and updated outlook, published on 05/21/2026 for the quarter ended 04/30/2026, provide fresh data points for US investors evaluating its contact-lens and women’s-health businesses. With its two-segment structure of CooperVision and CooperSurgical, the company remains positioned in healthcare markets that are influenced by demographic trends and clinical practice patterns. How management executes on product innovation, capacity investments and margin initiatives described in its fiscal 2025 and fiscal Q2 2026 filings will be important for the stock’s future performance on Nasdaq, where it continues to trade under the ticker COO in US dollars as of 05/22/2026.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.